|
Aug 13
|
Autolus Therapeutics PLC (AUTL) Q2 2025 Earnings Call Highlights: Strong Product Sales Amid ...
|
|
Aug 12
|
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
|
|
Jul 24
|
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
|
|
Jul 23
|
Discovering Opportunities: 3 Penny Stocks With Market Caps Over $200M
|
|
Jul 21
|
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
|
|
Jun 20
|
Syncona Ltd (LSE:SYNC) Full Year 2025 Earnings Call Highlights: Navigating Market Challenges ...
|
|
May 23
|
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
|
|
Dec 30
|
Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?
|